Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial

Edward D. Verrier, Stanton K. Shernan, Kenneth M. Taylor, Frans Van De Werf, Mark F. Newman, John C. Chen, Michel Carrier, Axel Haverich, Kevin J. Malloy, Peter X. Adams, Thomas G. Todaro, Christopher F. Mojcik, Scott A. Rollins, Jerrold H. Levy

Research output: Contribution to journalArticlepeer-review

184 Citations (SciVal)


Context. Inflammation and ischemia-reperfusion injury during coronary artery bypass graft (CABG) surgery requiring cardiopulmonary bypass are associated with post-operative myocardial infarction (MI) and mortality. Objective. To determine the efficacy and safety of pexelizumab, a C5 complement inhibitor, in reducing perioperative MI and mortality in CABG surgery. Design, Setting, and Participants. A randomized, double-blind, placebo-controlled trial, including 3099 patients (≥ 18 years) undergoing CABG surgery with or without valve surgery at 205 hospitals in North America and Western Europe from January 2002 to February 2003. Interventions. Patients were randomly assigned to receive intravenous pexelizumab (2.0 mg/kg bolus plus 0.05 mg/kg per hour for 24 hours; n=1553) or placebo (n=1546) 10 minutes before undergoing the procedure. Main Outcome Measures. The primary composite end point was the incidence of death or MI within 30 days of randomization in those undergoing CABG surgery only (n=2746). Secondary analyses included the intent-to-treat analyses of death or MI composite at days 4 and 30 in all 3099 study patients. Results. After 30 days, 134 (9.8%) of 1373 of patients receiving pexelizumab vs 161 (11.8%) of 1359 of patients receiving placebo (relative risk, 0.82; 95% confidence interval, 0.66-1.02; P=.07) died or experienced MI in the CABG surgery only population. In the intent-to-treat analyses, 178 (11.5%) of 1547 patients receiving pexelizumab vs 215 (14.0%) of 1535 receiving placebo died or experienced MI (relative risk, 0.82; 95% confidence interval, 0.68-0.99; P=.03). The trial was not powered to detect a reduction in mortality alone. Conclusions. Compared with placebo, pexelizumab was not associated with a significant reduction in the risk of the composite end point of death or MI in 2746 patients who had undergone CABG surgery only but was associated with a statistically significant risk reduction 30 days after the procedure among all 3099 patients undergoing CABG with or without valve surgery.

Original languageEnglish
Pages (from-to)2319-2327
Number of pages9
JournalJAMA - Journal of the American Medical Association
Issue number19
StatePublished - May 19 2004

ASJC Scopus subject areas

  • Medicine (all)


Dive into the research topics of 'Terminal complement blockade with pexelizumab during coronary artery bypass graft surgery requiring cardiopulmonary bypass: A randomized trial'. Together they form a unique fingerprint.

Cite this